Telemedicine use among patients with metastatic breast cancer during the COVID‐19 pandemic: Differences by race, age, and region
Purpose Our objective was to describe differences in telemedicine use among women with metastatic breast cancer (mBC) by race, age, and geographic region. Methods This was a retrospective cohort study of women with recurrent or de novo mBC treated in US community cancer practices that initiated a ne...
Gespeichert in:
| Veröffentlicht in: | Pharmacoepidemiology and drug safety 2023-01, Vol.32 (1), p.66-72 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 72 |
|---|---|
| container_issue | 1 |
| container_start_page | 66 |
| container_title | Pharmacoepidemiology and drug safety |
| container_volume | 32 |
| creator | Calip, Gregory S. Cohen, Aaron Rohrer, Rebecca Wang, Xiaoliang Wang, Xiaoyan Webster, Amy Wu, Amy Griffith, Sandra D. Showalter, Timothy N. Miksad, Rebecca A. |
| description | Purpose
Our objective was to describe differences in telemedicine use among women with metastatic breast cancer (mBC) by race, age, and geographic region.
Methods
This was a retrospective cohort study of women with recurrent or de novo mBC treated in US community cancer practices that initiated a new line of therapy between March 2020 and February 2021. Multivariable modified Poisson regression models were used to calculate adjusted rate ratios (RR) and robust 95% confidence intervals (CI) associated with telemedicine visits within 90 days of therapy initiation.
Results
Overall, among 3412 women with mBC, 751 (22%) patients had telemedicine visits following therapy initiation, with lower risks observed among older women ( |
| doi_str_mv | 10.1002/pds.5541 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10091805</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2754364669</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4391-3815c1bbc5dea9ead8cfff3ae3517c1951b8167b79f0fd5d702a075a37e38b123</originalsourceid><addsrcrecordid>eNp1kc1u1DAQxy1ERdsFiSdAlrhwIK0ntpOYC0K7QCtVKhKFq-U4k11XibPYCdXeKp6AZ-RJcOgHHxIXe-T5-T_znyHkKbAjYCw_3jbxSEoBD8gBMKUykLJ8OMeSZ5Us1D45jPGSsZRT4hHZ5wUACCEOyLcL7LDHxlnnkU4RqekHv6ZbMzr0Y6RXbtzQHkcTx_RkaR0whdQabzHQZgou0eMG6fL88-nqx_V3UOmzb7B39hVdubbFgImNtN7RYCy-pGY9H76hAddu8I_JXmu6iE9u7wX59O7txfIkOzt_f7p8c5ZZwRVkvAJpoa6tbNAoNE1l27blBrmE0oKSUFdQlHWpWtY2silZblgpDS-RVzXkfEFe3-hupzo5tsleMJ3eBtebsNODcfrvjHcbvR6-6jRiBVWa5YK8uFUIw5cJ46h7Fy12nfE4TFHnJUghZF7N6PN_0MthCj75S5QUvBBFoX4L2jDEGLC97wbYXDbXabN63mxCn_3Z_T14t8oEZDfAletw918h_WH18ZfgT899rtE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2754364669</pqid></control><display><type>article</type><title>Telemedicine use among patients with metastatic breast cancer during the COVID‐19 pandemic: Differences by race, age, and region</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Calip, Gregory S. ; Cohen, Aaron ; Rohrer, Rebecca ; Wang, Xiaoliang ; Wang, Xiaoyan ; Webster, Amy ; Wu, Amy ; Griffith, Sandra D. ; Showalter, Timothy N. ; Miksad, Rebecca A.</creator><creatorcontrib>Calip, Gregory S. ; Cohen, Aaron ; Rohrer, Rebecca ; Wang, Xiaoliang ; Wang, Xiaoyan ; Webster, Amy ; Wu, Amy ; Griffith, Sandra D. ; Showalter, Timothy N. ; Miksad, Rebecca A.</creatorcontrib><description>Purpose
Our objective was to describe differences in telemedicine use among women with metastatic breast cancer (mBC) by race, age, and geographic region.
Methods
This was a retrospective cohort study of women with recurrent or de novo mBC treated in US community cancer practices that initiated a new line of therapy between March 2020 and February 2021. Multivariable modified Poisson regression models were used to calculate adjusted rate ratios (RR) and robust 95% confidence intervals (CI) associated with telemedicine visits within 90 days of therapy initiation.
Results
Overall, among 3412 women with mBC, 751 (22%) patients had telemedicine visits following therapy initiation, with lower risks observed among older women (<50 years: 24%; 50–64 years: 22%; 65–74 years: 21%; ≥75 years: 20%). Greater telemedicine use was observed among Asian women (35%) compared to White (21%), Black (18%), and Hispanic (21%) women. Fewer telemedicine visits occurred in Southern (12%) and Midwestern (17%) states versus Northeastern (37%) or Western (36%) states. In multivariable models, women ages ≥75 years had significantly lower risks of telemedicine visits (RR = 0.76, 95% CI 0.62–0.95) compared to ages <50 years. Compared to patients in Northeastern states, women in Midwestern (RR = 0.46, 95% CI 0.37–0.57) and Southern (RR = 0.31, 95% CI 0.26–0.37) states had significantly lower risks of telemedicine visits; but not women in Western states (RR = 0.96, 95% CI 0.83–1.12). No statistically significant differences in telemedicine use were found between racial groups in overall multivariable models.
Conclusions
In this study of community cancer practices, older mBC patients and those living in Southern and Midwestern states were less likely to have telemedicine visits. Preferences for communication and delivery of care may have implications for measurement of exposures and endpoints in pharmacoepidemiologic studies of cancer patients.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.5541</identifier><identifier>PMID: 36111444</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Inc</publisher><subject>Aged ; Breast cancer ; Breast Neoplasms - epidemiology ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Brief Report ; Brief Reports ; COVID-19 ; COVID-19 - epidemiology ; Female ; Humans ; Metastases ; Metastasis ; Middle Aged ; Pandemics ; Regression analysis ; Retrospective Studies ; Statistical analysis ; Telemedicine</subject><ispartof>Pharmacoepidemiology and drug safety, 2023-01, Vol.32 (1), p.66-72</ispartof><rights>2022 Flatiron Health, Inc. published by John Wiley & Sons Ltd.</rights><rights>2022 Flatiron Health, Inc. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4391-3815c1bbc5dea9ead8cfff3ae3517c1951b8167b79f0fd5d702a075a37e38b123</citedby><cites>FETCH-LOGICAL-c4391-3815c1bbc5dea9ead8cfff3ae3517c1951b8167b79f0fd5d702a075a37e38b123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpds.5541$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpds.5541$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36111444$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Calip, Gregory S.</creatorcontrib><creatorcontrib>Cohen, Aaron</creatorcontrib><creatorcontrib>Rohrer, Rebecca</creatorcontrib><creatorcontrib>Wang, Xiaoliang</creatorcontrib><creatorcontrib>Wang, Xiaoyan</creatorcontrib><creatorcontrib>Webster, Amy</creatorcontrib><creatorcontrib>Wu, Amy</creatorcontrib><creatorcontrib>Griffith, Sandra D.</creatorcontrib><creatorcontrib>Showalter, Timothy N.</creatorcontrib><creatorcontrib>Miksad, Rebecca A.</creatorcontrib><title>Telemedicine use among patients with metastatic breast cancer during the COVID‐19 pandemic: Differences by race, age, and region</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidemiol Drug Saf</addtitle><description>Purpose
Our objective was to describe differences in telemedicine use among women with metastatic breast cancer (mBC) by race, age, and geographic region.
Methods
This was a retrospective cohort study of women with recurrent or de novo mBC treated in US community cancer practices that initiated a new line of therapy between March 2020 and February 2021. Multivariable modified Poisson regression models were used to calculate adjusted rate ratios (RR) and robust 95% confidence intervals (CI) associated with telemedicine visits within 90 days of therapy initiation.
Results
Overall, among 3412 women with mBC, 751 (22%) patients had telemedicine visits following therapy initiation, with lower risks observed among older women (<50 years: 24%; 50–64 years: 22%; 65–74 years: 21%; ≥75 years: 20%). Greater telemedicine use was observed among Asian women (35%) compared to White (21%), Black (18%), and Hispanic (21%) women. Fewer telemedicine visits occurred in Southern (12%) and Midwestern (17%) states versus Northeastern (37%) or Western (36%) states. In multivariable models, women ages ≥75 years had significantly lower risks of telemedicine visits (RR = 0.76, 95% CI 0.62–0.95) compared to ages <50 years. Compared to patients in Northeastern states, women in Midwestern (RR = 0.46, 95% CI 0.37–0.57) and Southern (RR = 0.31, 95% CI 0.26–0.37) states had significantly lower risks of telemedicine visits; but not women in Western states (RR = 0.96, 95% CI 0.83–1.12). No statistically significant differences in telemedicine use were found between racial groups in overall multivariable models.
Conclusions
In this study of community cancer practices, older mBC patients and those living in Southern and Midwestern states were less likely to have telemedicine visits. Preferences for communication and delivery of care may have implications for measurement of exposures and endpoints in pharmacoepidemiologic studies of cancer patients.</description><subject>Aged</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Brief Report</subject><subject>Brief Reports</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Pandemics</subject><subject>Regression analysis</subject><subject>Retrospective Studies</subject><subject>Statistical analysis</subject><subject>Telemedicine</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAQxy1ERdsFiSdAlrhwIK0ntpOYC0K7QCtVKhKFq-U4k11XibPYCdXeKp6AZ-RJcOgHHxIXe-T5-T_znyHkKbAjYCw_3jbxSEoBD8gBMKUykLJ8OMeSZ5Us1D45jPGSsZRT4hHZ5wUACCEOyLcL7LDHxlnnkU4RqekHv6ZbMzr0Y6RXbtzQHkcTx_RkaR0whdQabzHQZgou0eMG6fL88-nqx_V3UOmzb7B39hVdubbFgImNtN7RYCy-pGY9H76hAddu8I_JXmu6iE9u7wX59O7txfIkOzt_f7p8c5ZZwRVkvAJpoa6tbNAoNE1l27blBrmE0oKSUFdQlHWpWtY2silZblgpDS-RVzXkfEFe3-hupzo5tsleMJ3eBtebsNODcfrvjHcbvR6-6jRiBVWa5YK8uFUIw5cJ46h7Fy12nfE4TFHnJUghZF7N6PN_0MthCj75S5QUvBBFoX4L2jDEGLC97wbYXDbXabN63mxCn_3Z_T14t8oEZDfAletw918h_WH18ZfgT899rtE</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>Calip, Gregory S.</creator><creator>Cohen, Aaron</creator><creator>Rohrer, Rebecca</creator><creator>Wang, Xiaoliang</creator><creator>Wang, Xiaoyan</creator><creator>Webster, Amy</creator><creator>Wu, Amy</creator><creator>Griffith, Sandra D.</creator><creator>Showalter, Timothy N.</creator><creator>Miksad, Rebecca A.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202301</creationdate><title>Telemedicine use among patients with metastatic breast cancer during the COVID‐19 pandemic: Differences by race, age, and region</title><author>Calip, Gregory S. ; Cohen, Aaron ; Rohrer, Rebecca ; Wang, Xiaoliang ; Wang, Xiaoyan ; Webster, Amy ; Wu, Amy ; Griffith, Sandra D. ; Showalter, Timothy N. ; Miksad, Rebecca A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4391-3815c1bbc5dea9ead8cfff3ae3517c1951b8167b79f0fd5d702a075a37e38b123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Aged</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Brief Report</topic><topic>Brief Reports</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Pandemics</topic><topic>Regression analysis</topic><topic>Retrospective Studies</topic><topic>Statistical analysis</topic><topic>Telemedicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Calip, Gregory S.</creatorcontrib><creatorcontrib>Cohen, Aaron</creatorcontrib><creatorcontrib>Rohrer, Rebecca</creatorcontrib><creatorcontrib>Wang, Xiaoliang</creatorcontrib><creatorcontrib>Wang, Xiaoyan</creatorcontrib><creatorcontrib>Webster, Amy</creatorcontrib><creatorcontrib>Wu, Amy</creatorcontrib><creatorcontrib>Griffith, Sandra D.</creatorcontrib><creatorcontrib>Showalter, Timothy N.</creatorcontrib><creatorcontrib>Miksad, Rebecca A.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Calip, Gregory S.</au><au>Cohen, Aaron</au><au>Rohrer, Rebecca</au><au>Wang, Xiaoliang</au><au>Wang, Xiaoyan</au><au>Webster, Amy</au><au>Wu, Amy</au><au>Griffith, Sandra D.</au><au>Showalter, Timothy N.</au><au>Miksad, Rebecca A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Telemedicine use among patients with metastatic breast cancer during the COVID‐19 pandemic: Differences by race, age, and region</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidemiol Drug Saf</addtitle><date>2023-01</date><risdate>2023</risdate><volume>32</volume><issue>1</issue><spage>66</spage><epage>72</epage><pages>66-72</pages><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>Purpose
Our objective was to describe differences in telemedicine use among women with metastatic breast cancer (mBC) by race, age, and geographic region.
Methods
This was a retrospective cohort study of women with recurrent or de novo mBC treated in US community cancer practices that initiated a new line of therapy between March 2020 and February 2021. Multivariable modified Poisson regression models were used to calculate adjusted rate ratios (RR) and robust 95% confidence intervals (CI) associated with telemedicine visits within 90 days of therapy initiation.
Results
Overall, among 3412 women with mBC, 751 (22%) patients had telemedicine visits following therapy initiation, with lower risks observed among older women (<50 years: 24%; 50–64 years: 22%; 65–74 years: 21%; ≥75 years: 20%). Greater telemedicine use was observed among Asian women (35%) compared to White (21%), Black (18%), and Hispanic (21%) women. Fewer telemedicine visits occurred in Southern (12%) and Midwestern (17%) states versus Northeastern (37%) or Western (36%) states. In multivariable models, women ages ≥75 years had significantly lower risks of telemedicine visits (RR = 0.76, 95% CI 0.62–0.95) compared to ages <50 years. Compared to patients in Northeastern states, women in Midwestern (RR = 0.46, 95% CI 0.37–0.57) and Southern (RR = 0.31, 95% CI 0.26–0.37) states had significantly lower risks of telemedicine visits; but not women in Western states (RR = 0.96, 95% CI 0.83–1.12). No statistically significant differences in telemedicine use were found between racial groups in overall multivariable models.
Conclusions
In this study of community cancer practices, older mBC patients and those living in Southern and Midwestern states were less likely to have telemedicine visits. Preferences for communication and delivery of care may have implications for measurement of exposures and endpoints in pharmacoepidemiologic studies of cancer patients.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Inc</pub><pmid>36111444</pmid><doi>10.1002/pds.5541</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1053-8569 |
| ispartof | Pharmacoepidemiology and drug safety, 2023-01, Vol.32 (1), p.66-72 |
| issn | 1053-8569 1099-1557 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10091805 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Breast cancer Breast Neoplasms - epidemiology Breast Neoplasms - pathology Breast Neoplasms - therapy Brief Report Brief Reports COVID-19 COVID-19 - epidemiology Female Humans Metastases Metastasis Middle Aged Pandemics Regression analysis Retrospective Studies Statistical analysis Telemedicine |
| title | Telemedicine use among patients with metastatic breast cancer during the COVID‐19 pandemic: Differences by race, age, and region |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T23%3A55%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Telemedicine%20use%20among%20patients%20with%20metastatic%20breast%20cancer%20during%20the%20COVID%E2%80%9019%20pandemic:%20Differences%20by%20race,%20age,%20and%20region&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Calip,%20Gregory%20S.&rft.date=2023-01&rft.volume=32&rft.issue=1&rft.spage=66&rft.epage=72&rft.pages=66-72&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.5541&rft_dat=%3Cproquest_pubme%3E2754364669%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2754364669&rft_id=info:pmid/36111444&rfr_iscdi=true |